Sign up to access all valuation multiples
Tristel PLC is a player in the healthcare platform. The company is a manufacturer of chlorine dioxide chemistry used for the decontamination of medical devices. Its operating segments include three sectors, Hospital medical device decontamination products which are used predominantly for infection control in hospitals; manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from Hospital medical device decontamination.
2003
230
LTM Revenue $63.5M
LTM EBITDA $17.7M
$224M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tristel has a last 12-month revenue (LTM) of $63.5M and a last 12-month EBITDA of $17.7M.
In the most recent fiscal year, Tristel achieved revenue of $56.3M and an EBITDA of $13.4M.
Tristel expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tristel valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $63.5M | XXX | $56.3M | XXX | XXX | XXX |
| Gross Profit | $51.7M | XXX | $45.1M | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | 80% | XXX | XXX | XXX |
| EBITDA | $17.7M | XXX | $13.4M | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 24% | XXX | XXX | XXX |
| EBIT | $13.8M | XXX | $9.4M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $10.1M | XXX | $8.7M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Tristel's stock price is GBP 4 (or $5).
Tristel has current market cap of GBP 173M (or $232M), and EV of GBP 167M (or $224M).
See Tristel trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $224M | $232M | XXX | XXX | XXX | XXX | $0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Tristel has market cap of $232M and EV of $224M.
Tristel's trades at 3.8x EV/Revenue multiple, and 14.6x EV/EBITDA.
Equity research analysts estimate Tristel's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tristel has a P/E ratio of 23.1x.
See valuation multiples for Tristel and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $232M | XXX | $232M | XXX | XXX | XXX |
| EV (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | 12.7x | XXX | 14.6x | XXX | XXX | XXX |
| EV/EBIT | 16.2x | XXX | 19.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 23.1x | XXX | 25.1x | XXX | XXX | XXX |
| EV/FCF | 20.8x | XXX | 20.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTristel's last 12 month revenue growth is 10%
Tristel's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Tristel's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tristel's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tristel and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tristel acquired XXX companies to date.
Last acquisition by Tristel was XXXXXXXX, XXXXX XXXXX XXXXXX . Tristel acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Tristel founded? | Tristel was founded in 2003. |
| Where is Tristel headquartered? | Tristel is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Tristel have? | As of today, Tristel has 230 employees. |
| Who is the CEO of Tristel? | Tristel's CEO is Mr. Matthew Giovanni Sassone. |
| Is Tristel publicy listed? | Yes, Tristel is a public company listed on LON. |
| What is the stock symbol of Tristel? | Tristel trades under TSTL ticker. |
| When did Tristel go public? | Tristel went public in 2005. |
| Who are competitors of Tristel? | Similar companies to Tristel include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Tristel? | Tristel's current market cap is $232M |
| What is the current revenue of Tristel? | Tristel's last 12 months revenue is $63.5M. |
| What is the current revenue growth of Tristel? | Tristel revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Tristel? | Current revenue multiple of Tristel is 3.5x. |
| Is Tristel profitable? | Yes, Tristel is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tristel? | Tristel's last 12 months EBITDA is $17.7M. |
| What is Tristel's EBITDA margin? | Tristel's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Tristel? | Current EBITDA multiple of Tristel is 12.7x. |
| What is the current FCF of Tristel? | Tristel's last 12 months FCF is $10.8M. |
| What is Tristel's FCF margin? | Tristel's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Tristel? | Current FCF multiple of Tristel is 20.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
